Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-03-07 12:29 pm Sale | 2024-02-29 | 13G | Merrimack Pharmaceuticals, Inc. MACK | BlackRock Inc. BLK | 715,279 4.990% | -28,344 (-3.81%) | Filing History |
| 2024-02-22 4:46 pm Purchase | 2024-02-13 | 13G | Merrimack Pharmaceuticals, Inc. MACK | ADAR1 Partners LP | 902,350 6.300% | 902,350 (New Position) | Filing History |
| 2024-02-14 4:20 pm Sale | 2023-12-31 | 13G | Merrimack Pharmaceuticals, Inc. MACK | 22NW Fund, LP | 0 0.000% | -1,015,048 (Position Closed) | Filing History |
| 2024-01-31 2:08 pm Purchase | 2023-12-31 | 13G | Merrimack Pharmaceuticals, Inc. MACK | BlackRock Inc. BLK | 743,623 5.200% | 422,576 (+131.62%) | Filing History |
| 2024-01-25 4:05 pm Purchase | 2023-01-17 | 13D | Merrimack Pharmaceuticals, Inc. MACK | Newtyn Management, LLC | 1,873,694 13.100% | 354,587 (+23.34%) | Filing History |
| 2023-12-13 4:05 pm Purchase | 2023-12-07 | 13D | Merrimack Pharmaceuticals, Inc. MACK | Western Standard LLC | 2,220,058 15.500% | 228,950 (+11.50%) | Filing History |
| 2023-08-14 4:05 pm Purchase | 2022-12-29 | 13D | Merrimack Pharmaceuticals, Inc. MACK | Western Standard LLC | 1,991,108 13.900% | 802,263 (+67.48%) | Filing History |
| 2023-02-14 4:04 pm Sale | 2022-12-31 | 13G | Merrimack Pharmaceuticals, Inc. MACK | Point72 Asset Management, L.P. | 0 0.000% | -900,981 (Position Closed) | Filing History |
| 2023-02-13 4:20 pm Purchase | 2022-12-31 | 13G | Merrimack Pharmaceuticals, Inc. MACK | 22NW Fund, LP | 1,015,048 7.600% | 1,015,048 (New Position) | Filing History |
| 2022-08-04 4:28 pm Purchase | 2022-08-03 | 13G | Merrimack Pharmaceuticals, Inc. MACK | Point72 Asset Management, L.P. | 900,981 6.700% | 900,981 (New Position) | Filing History |
| 2022-02-14 12:50 pm Unchanged | 2021-12-31 | 13G | Merrimack Pharmaceuticals, Inc. MACK | 22NW LP | 1,241,896 9.300% | 0 (Unchanged) | Filing History |
| 2022-02-14 08:19 am Sale | 2021-12-31 | 13G | Merrimack Pharmaceuticals, Inc. MACK | Nantahala Capital Management, LLC | 569,971 4.300% | -181,872 (-24.19%) | Filing History |
| 2021-02-12 5:13 pm Sale | 2021-02-16 | 13G | Merrimack Pharmaceuticals, Inc. MACK | DIMENSIONAL FUND ADVISORS LP | 550,539 4.100% | -122,591 (-18.21%) | Filing History |
| 2021-02-12 4:01 pm Purchase | 2020-12-31 | 13G | Merrimack Pharmaceuticals, Inc. MACK | 22NW LP | 1,241,896 9.280% | 289,533 (+30.40%) | Filing History |
| 2021-02-12 06:46 am Purchase | 2020-12-31 | 13G | Merrimack Pharmaceuticals, Inc. MACK | Nantahala Capital Management, LLC | 751,843 5.600% | 4,208 (+0.56%) | Filing History |
| 2020-12-02 7:21 pm Purchase | 2020-11-24 | 13D | Merrimack Pharmaceuticals, Inc. MACK | Western Standard LLC | 1,188,845 8.900% | 142,217 (+13.59%) | Filing History |
| 2020-12-02 2:18 pm Purchase | 2020-11-24 | 13D | Merrimack Pharmaceuticals, Inc. MACK | Newtyn Management, LLC | 1,519,107 11.400% | 142,227 (+10.33%) | Filing History |
| 2020-07-24 5:42 pm Purchase | 2020-07-22 | 13D | Merrimack Pharmaceuticals, Inc. MACK | Newtyn Management, LLC | 1,376,880 10.300% | 203,714 (+17.36%) | Filing History |
| 2020-07-23 8:44 pm Purchase | 2020-07-22 | 13D | Merrimack Pharmaceuticals, Inc. MACK | Western Standard LLC | 1,046,628 7.800% | 203,715 (+24.17%) | Filing History |